nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—CYP1A2—Dacarbazine—sarcoma	0.0492	0.671	CbGbCtD
Rasagiline—CYP1A2—Etoposide—sarcoma	0.0241	0.328	CbGbCtD
Rasagiline—BCL2—hematopoietic system—sarcoma	0.00735	0.0915	CbGeAlD
Rasagiline—BCL2—connective tissue—sarcoma	0.00707	0.0881	CbGeAlD
Rasagiline—BCL2—EPO signaling pathway—PLCG1—sarcoma	0.0067	0.0284	CbGpPWpGaD
Rasagiline—BCL2—smooth muscle tissue—sarcoma	0.00647	0.0806	CbGeAlD
Rasagiline—BCL2—skin of body—sarcoma	0.00639	0.0795	CbGeAlD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—MITF—sarcoma	0.00606	0.0257	CbGpPWpGaD
Rasagiline—BCL2—uterus—sarcoma	0.00555	0.0691	CbGeAlD
Rasagiline—BCL2—Kit receptor signaling pathway—MITF—sarcoma	0.00539	0.0228	CbGpPWpGaD
Rasagiline—BCL2—lymphoid tissue—sarcoma	0.00517	0.0644	CbGeAlD
Rasagiline—BCL2—Integrated Cancer Pathway—ATF1—sarcoma	0.00493	0.0209	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—ATF1—sarcoma	0.00493	0.0209	CbGpPWpGaD
Rasagiline—BCL2—bone marrow—sarcoma	0.00471	0.0587	CbGeAlD
Rasagiline—BCL2—Estrogen signaling pathway—CREB1—sarcoma	0.00449	0.019	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CD34—sarcoma	0.00437	0.0185	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—MYOD1—sarcoma	0.00437	0.0185	CbGpPWpGaD
Rasagiline—BCL2—TP53 Network—MDM2—sarcoma	0.00433	0.0183	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—PLCG1—sarcoma	0.0041	0.0174	CbGpPWpGaD
Rasagiline—BCL2—testis—sarcoma	0.00403	0.0501	CbGeAlD
Rasagiline—MAOB—myometrium—sarcoma	0.00356	0.0444	CbGeAlD
Rasagiline—BCL2—Direct p53 effectors—COL18A1—sarcoma	0.00345	0.0146	CbGpPWpGaD
Rasagiline—MAOB—embryo—sarcoma	0.00343	0.0427	CbGeAlD
Rasagiline—BCL2—Estrogen signaling pathway—JUN—sarcoma	0.00323	0.0137	CbGpPWpGaD
Rasagiline—MAOB—seminal vesicle—sarcoma	0.00322	0.0401	CbGeAlD
Rasagiline—MAOB—hematopoietic system—sarcoma	0.00306	0.0381	CbGeAlD
Rasagiline—BCL2—TP53 Network—MYC—sarcoma	0.00302	0.0128	CbGpPWpGaD
Rasagiline—MAOB—connective tissue—sarcoma	0.00295	0.0367	CbGeAlD
Rasagiline—BCL2—lymph node—sarcoma	0.00292	0.0363	CbGeAlD
Rasagiline—BCL2—Corticotropin-releasing hormone—PLCG1—sarcoma	0.00288	0.0122	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—PDGFRA—sarcoma	0.00286	0.0121	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—PDGFRB—sarcoma	0.00276	0.0117	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—IL2—sarcoma	0.00268	0.0114	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—CREB1—sarcoma	0.00267	0.0113	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—KIT—sarcoma	0.00249	0.0106	CbGpPWpGaD
Rasagiline—BCL2—TP53 Network—TP53—sarcoma	0.00248	0.0105	CbGpPWpGaD
Rasagiline—MAOB—Alpha-synuclein signaling—SRC—sarcoma	0.00235	0.00994	CbGpPWpGaD
Rasagiline—MAOB—cardiac atrium—sarcoma	0.00232	0.0289	CbGeAlD
Rasagiline—MAOB—uterus—sarcoma	0.00231	0.0288	CbGeAlD
Rasagiline—BCL2—Apoptosis—IGF1R—sarcoma	0.00231	0.00977	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—IL2—sarcoma	0.00227	0.00961	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—KIT—sarcoma	0.00222	0.0094	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—MDM2—sarcoma	0.00221	0.00936	CbGpPWpGaD
Rasagiline—MAOB—Tryptophan metabolism—MDM2—sarcoma	0.0022	0.0093	CbGpPWpGaD
Rasagiline—CYP1A2—hematopoietic system—sarcoma	0.00218	0.0271	CbGeAlD
Rasagiline—BCL2—IL-5 Signaling Pathway—IL2—sarcoma	0.00213	0.00903	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—CREB1—sarcoma	0.00211	0.00895	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.00211	0.00893	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—MYC—sarcoma	0.0021	0.00889	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—JUN—sarcoma	0.00207	0.00878	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—IL2—sarcoma	0.00205	0.00868	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—VEGFC—sarcoma	0.00205	0.00868	CbGpPWpGaD
Rasagiline—MAOB—tendon—sarcoma	0.00202	0.0252	CbGeAlD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CREB1—sarcoma	0.002	0.00849	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—JUN—sarcoma	0.00199	0.00845	CbGpPWpGaD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—JUN—sarcoma	0.00199	0.00845	CbGpPWpGaD
Rasagiline—BCL2—Activation of BH3-only proteins—TP53—sarcoma	0.00199	0.00844	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—MMP2—sarcoma	0.00197	0.00833	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IGF1R—sarcoma	0.00193	0.00817	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.00184	0.00779	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—MYC—sarcoma	0.00177	0.00751	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—JUN—sarcoma	0.00176	0.00747	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—SRC—sarcoma	0.00172	0.0073	CbGpPWpGaD
Rasagiline—MAOB—testis—sarcoma	0.00168	0.0209	CbGeAlD
Rasagiline—BCL2—IL2-mediated signaling events—IL2—sarcoma	0.00168	0.0071	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—KIT—sarcoma	0.00167	0.00709	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—MYC—sarcoma	0.00167	0.00706	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—FLT1—sarcoma	0.00164	0.00694	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—JUN—sarcoma	0.00163	0.00691	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—MYC—sarcoma	0.0016	0.00679	CbGpPWpGaD
Rasagiline—MAOB—liver—sarcoma	0.00158	0.0197	CbGeAlD
Rasagiline—BCL2—IL-3 Signaling Pathway—SRC—sarcoma	0.00158	0.0067	CbGpPWpGaD
Rasagiline—BCL2—EPO signaling pathway—HRAS—sarcoma	0.00156	0.00663	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—MYC—sarcoma	0.00154	0.00654	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—KRAS—sarcoma	0.00154	0.00652	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—CCND1—sarcoma	0.00152	0.00645	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—JUN—sarcoma	0.00152	0.00643	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CREB1—sarcoma	0.00148	0.00627	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CCND1—sarcoma	0.00144	0.00612	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—MYC—sarcoma	0.00144	0.0061	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TP53—sarcoma	0.00143	0.00604	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—TP53—sarcoma	0.00143	0.00604	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—NRAS—sarcoma	0.00141	0.00596	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.00137	0.00582	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—SRC—sarcoma	0.00136	0.00577	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—MDM2—sarcoma	0.00132	0.00558	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—MYC—sarcoma	0.00131	0.00555	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—TP53—sarcoma	0.00127	0.00537	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—HRAS—sarcoma	0.00126	0.00533	CbGpPWpGaD
Rasagiline—CYP1A2—Melatonin metabolism and effects—FOXO1—sarcoma	0.00122	0.00519	CbGpPWpGaD
Rasagiline—MAOB—lymph node—sarcoma	0.00122	0.0151	CbGeAlD
Rasagiline—CYP1A2—Estrogen Receptor Pathway—JUN—sarcoma	0.00121	0.00514	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—HRAS—sarcoma	0.00121	0.00514	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—KRAS—sarcoma	0.00121	0.00513	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—IGF1R—sarcoma	0.0012	0.00509	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—MYC—sarcoma	0.00116	0.00491	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CCND1—sarcoma	0.00115	0.00486	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—JUN—sarcoma	0.00114	0.00485	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PDGFRB—sarcoma	0.00114	0.00483	CbGpPWpGaD
Rasagiline—CYP1A2—liver—sarcoma	0.00113	0.014	CbGeAlD
Rasagiline—BCL2—Focal Adhesion—PDGFRA—sarcoma	0.00112	0.00476	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.00112	0.00474	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—HRAS—sarcoma	0.00111	0.00471	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—MDM2—sarcoma	0.0011	0.00467	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—IL2—sarcoma	0.00109	0.00464	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—HRAS—sarcoma	0.00108	0.00456	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—JUN—sarcoma	0.00107	0.00455	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MDM2—sarcoma	0.00107	0.00453	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CTNNB1—sarcoma	0.00106	0.00448	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—HRAS—sarcoma	0.00103	0.00436	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000996	0.00422	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—NRAS—sarcoma	0.000988	0.00419	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MMP2—sarcoma	0.000985	0.00417	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—HRAS—sarcoma	0.000959	0.00406	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—JUN—sarcoma	0.000958	0.00406	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—KDR—sarcoma	0.000945	0.004	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CCND1—sarcoma	0.000932	0.00395	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—JUN—sarcoma	0.00093	0.00394	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CTNNB1—sarcoma	0.000922	0.00391	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—MYC—sarcoma	0.00092	0.0039	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—MYC—sarcoma	0.00092	0.0039	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MDM2—sarcoma	0.000875	0.00371	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—SRC—sarcoma	0.000859	0.00364	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—KRAS—sarcoma	0.00085	0.0036	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000825	0.0035	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MDM2—sarcoma	0.000824	0.00349	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—NRAS—sarcoma	0.000802	0.0034	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—JUN—sarcoma	0.000761	0.00322	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—sarcoma	0.000756	0.0032	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MYC—sarcoma	0.000747	0.00317	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—HRAS—sarcoma	0.000723	0.00306	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CCND1—sarcoma	0.000718	0.00304	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—JUN—sarcoma	0.000716	0.00303	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	0.000711	0.00301	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—sarcoma	0.000709	0.003	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CTNNB1—sarcoma	0.000696	0.00295	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—KRAS—sarcoma	0.00069	0.00292	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000683	0.00289	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PLCG1—sarcoma	0.000662	0.00281	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—sarcoma	0.000632	0.00268	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—ATF1—sarcoma	0.000629	0.00266	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—VEGFA—sarcoma	0.000626	0.00265	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—sarcoma	0.000614	0.0026	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—HRAS—sarcoma	0.000605	0.00256	CbGpPWpGaD
Rasagiline—Face oedema—Doxorubicin—sarcoma	0.0006	0.000983	CcSEcCtD
Rasagiline—Hypersensitivity—Dactinomycin—sarcoma	0.0006	0.000982	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—EGFR—sarcoma	0.000598	0.00253	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CCND1—sarcoma	0.000597	0.00253	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—JUN—sarcoma	0.000596	0.00252	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000595	0.00252	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Vincristine—sarcoma	0.000595	0.000974	CcSEcCtD
Rasagiline—Confusional state—Etoposide—sarcoma	0.000594	0.000973	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000593	0.00251	CbGpPWpGaD
Rasagiline—Muscular weakness—Epirubicin—sarcoma	0.000592	0.000971	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—CTNNB1—sarcoma	0.000591	0.00251	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000589	0.00249	CbGpPWpGaD
Rasagiline—Mood swings—Doxorubicin—sarcoma	0.000589	0.000965	CcSEcCtD
Rasagiline—Asthenia—Thiotepa—sarcoma	0.000588	0.000964	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—HRAS—sarcoma	0.000587	0.00249	CbGpPWpGaD
Rasagiline—Infection—Etoposide—sarcoma	0.000585	0.000959	CcSEcCtD
Rasagiline—Ataxia—Doxorubicin—sarcoma	0.000584	0.000957	CcSEcCtD
Rasagiline—Asthenia—Dactinomycin—sarcoma	0.000584	0.000956	CcSEcCtD
Rasagiline—Feeling abnormal—Mitoxantrone—sarcoma	0.000584	0.000956	CcSEcCtD
Rasagiline—Influenza—Epirubicin—sarcoma	0.000581	0.000951	CcSEcCtD
Rasagiline—Dysphagia—Epirubicin—sarcoma	0.000581	0.000951	CcSEcCtD
Rasagiline—Asthma—Epirubicin—sarcoma	0.000581	0.000951	CcSEcCtD
Rasagiline—Pruritus—Thiotepa—sarcoma	0.00058	0.00095	CcSEcCtD
Rasagiline—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000579	0.000949	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MYC—sarcoma	0.000576	0.00244	CbGpPWpGaD
Rasagiline—Body temperature increased—Vincristine—sarcoma	0.000575	0.000942	CcSEcCtD
Rasagiline—Abdominal pain—Vincristine—sarcoma	0.000575	0.000942	CcSEcCtD
Rasagiline—Liver function test abnormal—Doxorubicin—sarcoma	0.000574	0.00094	CcSEcCtD
Rasagiline—Skin disorder—Etoposide—sarcoma	0.000572	0.000937	CcSEcCtD
Rasagiline—Hyperhidrosis—Etoposide—sarcoma	0.000569	0.000933	CcSEcCtD
Rasagiline—Orthostatic hypotension—Doxorubicin—sarcoma	0.000568	0.00093	CcSEcCtD
Rasagiline—Angina pectoris—Epirubicin—sarcoma	0.000566	0.000926	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.000563	0.00239	CbGpPWpGaD
Rasagiline—Urticaria—Mitoxantrone—sarcoma	0.000563	0.000922	CcSEcCtD
Rasagiline—Anorexia—Etoposide—sarcoma	0.000561	0.00092	CcSEcCtD
Rasagiline—Diarrhoea—Thiotepa—sarcoma	0.000561	0.000919	CcSEcCtD
Rasagiline—Body temperature increased—Mitoxantrone—sarcoma	0.00056	0.000917	CcSEcCtD
Rasagiline—Abdominal pain—Mitoxantrone—sarcoma	0.00056	0.000917	CcSEcCtD
Rasagiline—Diarrhoea—Dactinomycin—sarcoma	0.000557	0.000912	CcSEcCtD
Rasagiline—Hypotension—Etoposide—sarcoma	0.00055	0.000902	CcSEcCtD
Rasagiline—Muscular weakness—Doxorubicin—sarcoma	0.000548	0.000898	CcSEcCtD
Rasagiline—BCL2—Immune System—CD34—sarcoma	0.000545	0.00231	CbGpPWpGaD
Rasagiline—Dysuria—Epirubicin—sarcoma	0.000543	0.000889	CcSEcCtD
Rasagiline—Dizziness—Thiotepa—sarcoma	0.000542	0.000888	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Epirubicin—sarcoma	0.00054	0.000884	CcSEcCtD
Rasagiline—Dysphagia—Doxorubicin—sarcoma	0.000537	0.00088	CcSEcCtD
Rasagiline—Influenza—Doxorubicin—sarcoma	0.000537	0.00088	CcSEcCtD
Rasagiline—Asthma—Doxorubicin—sarcoma	0.000537	0.00088	CcSEcCtD
Rasagiline—Pollakiuria—Epirubicin—sarcoma	0.000536	0.000879	CcSEcCtD
Rasagiline—Hypersensitivity—Vincristine—sarcoma	0.000536	0.000878	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—SRC—sarcoma	0.000535	0.00226	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000532	0.00226	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—KRAS—sarcoma	0.000532	0.00225	CbGpPWpGaD
Rasagiline—Photosensitivity reaction—Epirubicin—sarcoma	0.00053	0.000868	CcSEcCtD
Rasagiline—Paraesthesia—Etoposide—sarcoma	0.000529	0.000866	CcSEcCtD
Rasagiline—Weight decreased—Epirubicin—sarcoma	0.000525	0.00086	CcSEcCtD
Rasagiline—Dyspnoea—Etoposide—sarcoma	0.000525	0.00086	CcSEcCtD
Rasagiline—Somnolence—Etoposide—sarcoma	0.000524	0.000858	CcSEcCtD
Rasagiline—Angina pectoris—Doxorubicin—sarcoma	0.000523	0.000857	CcSEcCtD
Rasagiline—Hypersensitivity—Mitoxantrone—sarcoma	0.000522	0.000855	CcSEcCtD
Rasagiline—Asthenia—Vincristine—sarcoma	0.000522	0.000855	CcSEcCtD
Rasagiline—Vomiting—Thiotepa—sarcoma	0.000521	0.000854	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—VEGFA—sarcoma	0.000521	0.00221	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000518	0.0022	CbGpPWpGaD
Rasagiline—Infestation NOS—Epirubicin—sarcoma	0.000518	0.000848	CcSEcCtD
Rasagiline—Infestation—Epirubicin—sarcoma	0.000518	0.000848	CcSEcCtD
Rasagiline—Vomiting—Dactinomycin—sarcoma	0.000517	0.000848	CcSEcCtD
Rasagiline—Rash—Thiotepa—sarcoma	0.000517	0.000847	CcSEcCtD
Rasagiline—Dermatitis—Thiotepa—sarcoma	0.000517	0.000846	CcSEcCtD
Rasagiline—Headache—Thiotepa—sarcoma	0.000514	0.000841	CcSEcCtD
Rasagiline—Rash—Dactinomycin—sarcoma	0.000513	0.000841	CcSEcCtD
Rasagiline—Decreased appetite—Etoposide—sarcoma	0.000512	0.000839	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Etoposide—sarcoma	0.000508	0.000833	CcSEcCtD
Rasagiline—Asthenia—Mitoxantrone—sarcoma	0.000508	0.000832	CcSEcCtD
Rasagiline—CYP1A2—Tryptophan metabolism—MDM2—sarcoma	0.000508	0.00215	CbGpPWpGaD
Rasagiline—Neuropathy peripheral—Epirubicin—sarcoma	0.000507	0.000831	CcSEcCtD
Rasagiline—Jaundice—Epirubicin—sarcoma	0.000505	0.000827	CcSEcCtD
Rasagiline—Stomatitis—Epirubicin—sarcoma	0.000505	0.000827	CcSEcCtD
Rasagiline—Constipation—Etoposide—sarcoma	0.000504	0.000825	CcSEcCtD
Rasagiline—Conjunctivitis—Epirubicin—sarcoma	0.000503	0.000824	CcSEcCtD
Rasagiline—Dysuria—Doxorubicin—sarcoma	0.000502	0.000823	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—TP53—sarcoma	0.000502	0.00213	CbGpPWpGaD
Rasagiline—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000499	0.000818	CcSEcCtD
Rasagiline—Diarrhoea—Vincristine—sarcoma	0.000497	0.000815	CcSEcCtD
Rasagiline—Sweating—Epirubicin—sarcoma	0.000496	0.000813	CcSEcCtD
Rasagiline—Pollakiuria—Doxorubicin—sarcoma	0.000496	0.000813	CcSEcCtD
Rasagiline—Haematuria—Epirubicin—sarcoma	0.000494	0.000809	CcSEcCtD
Rasagiline—Photosensitivity reaction—Doxorubicin—sarcoma	0.00049	0.000803	CcSEcCtD
Rasagiline—Epistaxis—Epirubicin—sarcoma	0.000488	0.0008	CcSEcCtD
Rasagiline—Nausea—Thiotepa—sarcoma	0.000487	0.000798	CcSEcCtD
Rasagiline—Weight decreased—Doxorubicin—sarcoma	0.000486	0.000796	CcSEcCtD
Rasagiline—Feeling abnormal—Etoposide—sarcoma	0.000485	0.000795	CcSEcCtD
Rasagiline—Diarrhoea—Mitoxantrone—sarcoma	0.000484	0.000794	CcSEcCtD
Rasagiline—Nausea—Dactinomycin—sarcoma	0.000483	0.000792	CcSEcCtD
Rasagiline—Gastrointestinal pain—Etoposide—sarcoma	0.000482	0.000789	CcSEcCtD
Rasagiline—Dizziness—Vincristine—sarcoma	0.000481	0.000788	CcSEcCtD
Rasagiline—Infestation NOS—Doxorubicin—sarcoma	0.000479	0.000785	CcSEcCtD
Rasagiline—Infestation—Doxorubicin—sarcoma	0.000479	0.000785	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.000477	0.00202	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—sarcoma	0.000473	0.002	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—FOXO1—sarcoma	0.00047	0.00199	CbGpPWpGaD
Rasagiline—Neuropathy peripheral—Doxorubicin—sarcoma	0.00047	0.000769	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PDGFRB—sarcoma	0.000469	0.00199	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—EGFR—sarcoma	0.000469	0.00198	CbGpPWpGaD
Rasagiline—Urticaria—Etoposide—sarcoma	0.000468	0.000767	CcSEcCtD
Rasagiline—Haemoglobin—Epirubicin—sarcoma	0.000467	0.000765	CcSEcCtD
Rasagiline—Jaundice—Doxorubicin—sarcoma	0.000467	0.000765	CcSEcCtD
Rasagiline—Stomatitis—Doxorubicin—sarcoma	0.000467	0.000765	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.000467	0.00198	CbGpPWpGaD
Rasagiline—Rhinitis—Epirubicin—sarcoma	0.000466	0.000763	CcSEcCtD
Rasagiline—Abdominal pain—Etoposide—sarcoma	0.000466	0.000763	CcSEcCtD
Rasagiline—Body temperature increased—Etoposide—sarcoma	0.000466	0.000763	CcSEcCtD
Rasagiline—Conjunctivitis—Doxorubicin—sarcoma	0.000466	0.000763	CcSEcCtD
Rasagiline—Haemorrhage—Epirubicin—sarcoma	0.000465	0.000761	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TP53—sarcoma	0.000463	0.00196	CbGpPWpGaD
Rasagiline—Hypoaesthesia—Epirubicin—sarcoma	0.000462	0.000757	CcSEcCtD
Rasagiline—Vomiting—Vincristine—sarcoma	0.000462	0.000757	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PDGFRA—sarcoma	0.000462	0.00196	CbGpPWpGaD
Rasagiline—Sweating—Doxorubicin—sarcoma	0.000459	0.000752	CcSEcCtD
Rasagiline—Urinary tract disorder—Epirubicin—sarcoma	0.000459	0.000752	CcSEcCtD
Rasagiline—Rash—Vincristine—sarcoma	0.000458	0.000751	CcSEcCtD
Rasagiline—Dermatitis—Vincristine—sarcoma	0.000458	0.00075	CcSEcCtD
Rasagiline—Oedema peripheral—Epirubicin—sarcoma	0.000458	0.00075	CcSEcCtD
Rasagiline—Haematuria—Doxorubicin—sarcoma	0.000457	0.000748	CcSEcCtD
Rasagiline—Connective tissue disorder—Epirubicin—sarcoma	0.000457	0.000748	CcSEcCtD
Rasagiline—Urethral disorder—Epirubicin—sarcoma	0.000456	0.000746	CcSEcCtD
Rasagiline—Headache—Vincristine—sarcoma	0.000455	0.000746	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	0.000454	0.00192	CbGpPWpGaD
Rasagiline—Epistaxis—Doxorubicin—sarcoma	0.000452	0.00074	CcSEcCtD
Rasagiline—Vomiting—Mitoxantrone—sarcoma	0.00045	0.000738	CcSEcCtD
Rasagiline—Rash—Mitoxantrone—sarcoma	0.000446	0.000731	CcSEcCtD
Rasagiline—Dermatitis—Mitoxantrone—sarcoma	0.000446	0.000731	CcSEcCtD
Rasagiline—Headache—Mitoxantrone—sarcoma	0.000444	0.000727	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	0.000442	0.00187	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000441	0.00187	CbGpPWpGaD
Rasagiline—Eye disorder—Epirubicin—sarcoma	0.000434	0.000711	CcSEcCtD
Rasagiline—Hypersensitivity—Etoposide—sarcoma	0.000434	0.000711	CcSEcCtD
Rasagiline—Haemoglobin—Doxorubicin—sarcoma	0.000432	0.000708	CcSEcCtD
Rasagiline—Nausea—Vincristine—sarcoma	0.000432	0.000707	CcSEcCtD
Rasagiline—Cardiac disorder—Epirubicin—sarcoma	0.000431	0.000707	CcSEcCtD
Rasagiline—Rhinitis—Doxorubicin—sarcoma	0.000431	0.000706	CcSEcCtD
Rasagiline—Haemorrhage—Doxorubicin—sarcoma	0.00043	0.000704	CcSEcCtD
Rasagiline—Hypoaesthesia—Doxorubicin—sarcoma	0.000428	0.000701	CcSEcCtD
Rasagiline—Urinary tract disorder—Doxorubicin—sarcoma	0.000425	0.000696	CcSEcCtD
Rasagiline—Oedema peripheral—Doxorubicin—sarcoma	0.000424	0.000694	CcSEcCtD
Rasagiline—Asthenia—Etoposide—sarcoma	0.000423	0.000692	CcSEcCtD
Rasagiline—Connective tissue disorder—Doxorubicin—sarcoma	0.000423	0.000692	CcSEcCtD
Rasagiline—Angiopathy—Epirubicin—sarcoma	0.000422	0.000691	CcSEcCtD
Rasagiline—Urethral disorder—Doxorubicin—sarcoma	0.000421	0.00069	CcSEcCtD
Rasagiline—Nausea—Mitoxantrone—sarcoma	0.000421	0.000689	CcSEcCtD
Rasagiline—Immune system disorder—Epirubicin—sarcoma	0.00042	0.000688	CcSEcCtD
Rasagiline—Mediastinal disorder—Epirubicin—sarcoma	0.000419	0.000686	CcSEcCtD
Rasagiline—Chills—Epirubicin—sarcoma	0.000417	0.000683	CcSEcCtD
Rasagiline—Pruritus—Etoposide—sarcoma	0.000417	0.000683	CcSEcCtD
Rasagiline—Alopecia—Epirubicin—sarcoma	0.000411	0.000673	CcSEcCtD
Rasagiline—Mental disorder—Epirubicin—sarcoma	0.000407	0.000667	CcSEcCtD
Rasagiline—Malnutrition—Epirubicin—sarcoma	0.000405	0.000663	CcSEcCtD
Rasagiline—Diarrhoea—Etoposide—sarcoma	0.000403	0.00066	CcSEcCtD
Rasagiline—Eye disorder—Doxorubicin—sarcoma	0.000402	0.000658	CcSEcCtD
Rasagiline—Cardiac disorder—Doxorubicin—sarcoma	0.000399	0.000654	CcSEcCtD
Rasagiline—Flatulence—Epirubicin—sarcoma	0.000399	0.000653	CcSEcCtD
Rasagiline—Dysgeusia—Epirubicin—sarcoma	0.000396	0.000649	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	0.000396	0.00168	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000396	0.00168	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTPRC—sarcoma	0.000394	0.00167	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000392	0.00166	CbGpPWpGaD
Rasagiline—Back pain—Epirubicin—sarcoma	0.000391	0.000641	CcSEcCtD
Rasagiline—Angiopathy—Doxorubicin—sarcoma	0.00039	0.000639	CcSEcCtD
Rasagiline—Dizziness—Etoposide—sarcoma	0.000389	0.000638	CcSEcCtD
Rasagiline—Muscle spasms—Epirubicin—sarcoma	0.000389	0.000637	CcSEcCtD
Rasagiline—Immune system disorder—Doxorubicin—sarcoma	0.000388	0.000636	CcSEcCtD
Rasagiline—Mediastinal disorder—Doxorubicin—sarcoma	0.000388	0.000635	CcSEcCtD
Rasagiline—Chills—Doxorubicin—sarcoma	0.000386	0.000632	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000386	0.00163	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PLCG1—sarcoma	0.000386	0.00163	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000381	0.00161	CbGpPWpGaD
Rasagiline—Alopecia—Doxorubicin—sarcoma	0.00038	0.000622	CcSEcCtD
Rasagiline—Mental disorder—Doxorubicin—sarcoma	0.000377	0.000617	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—HRAS—sarcoma	0.000376	0.00159	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Epirubicin—sarcoma	0.000375	0.000615	CcSEcCtD
Rasagiline—Vomiting—Etoposide—sarcoma	0.000374	0.000613	CcSEcCtD
Rasagiline—Malnutrition—Doxorubicin—sarcoma	0.000374	0.000613	CcSEcCtD
Rasagiline—Anaemia—Epirubicin—sarcoma	0.000374	0.000613	CcSEcCtD
Rasagiline—Agitation—Epirubicin—sarcoma	0.000372	0.000609	CcSEcCtD
Rasagiline—Rash—Etoposide—sarcoma	0.000371	0.000608	CcSEcCtD
Rasagiline—Dermatitis—Etoposide—sarcoma	0.000371	0.000608	CcSEcCtD
Rasagiline—Headache—Etoposide—sarcoma	0.000369	0.000604	CcSEcCtD
Rasagiline—Flatulence—Doxorubicin—sarcoma	0.000369	0.000604	CcSEcCtD
Rasagiline—Dysgeusia—Doxorubicin—sarcoma	0.000367	0.0006	CcSEcCtD
Rasagiline—BCL2—Immune System—ATF1—sarcoma	0.000366	0.00155	CbGpPWpGaD
Rasagiline—Malaise—Epirubicin—sarcoma	0.000365	0.000598	CcSEcCtD
Rasagiline—Vertigo—Epirubicin—sarcoma	0.000363	0.000595	CcSEcCtD
Rasagiline—Syncope—Epirubicin—sarcoma	0.000363	0.000594	CcSEcCtD
Rasagiline—Leukopenia—Epirubicin—sarcoma	0.000362	0.000593	CcSEcCtD
Rasagiline—Back pain—Doxorubicin—sarcoma	0.000362	0.000593	CcSEcCtD
Rasagiline—MAOB—Metabolism—ENO2—sarcoma	0.000362	0.00153	CbGpPWpGaD
Rasagiline—Muscle spasms—Doxorubicin—sarcoma	0.00036	0.00059	CcSEcCtD
Rasagiline—MAOB—Metabolism—HBA1—sarcoma	0.000359	0.00152	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KIT—sarcoma	0.000358	0.00152	CbGpPWpGaD
Rasagiline—Loss of consciousness—Epirubicin—sarcoma	0.000356	0.000582	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000355	0.0015	CbGpPWpGaD
Rasagiline—Cough—Epirubicin—sarcoma	0.000353	0.000578	CcSEcCtD
Rasagiline—Convulsion—Epirubicin—sarcoma	0.00035	0.000574	CcSEcCtD
Rasagiline—Nausea—Etoposide—sarcoma	0.00035	0.000573	CcSEcCtD
Rasagiline—Hypertension—Epirubicin—sarcoma	0.000349	0.000572	CcSEcCtD
Rasagiline—Ill-defined disorder—Doxorubicin—sarcoma	0.000347	0.000569	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000347	0.00147	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	0.000347	0.00147	CbGpPWpGaD
Rasagiline—Anaemia—Doxorubicin—sarcoma	0.000346	0.000567	CcSEcCtD
Rasagiline—Chest pain—Epirubicin—sarcoma	0.000344	0.000564	CcSEcCtD
Rasagiline—Arthralgia—Epirubicin—sarcoma	0.000344	0.000564	CcSEcCtD
Rasagiline—Agitation—Doxorubicin—sarcoma	0.000344	0.000563	CcSEcCtD
Rasagiline—Anxiety—Epirubicin—sarcoma	0.000343	0.000562	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000342	0.00056	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CREB1—sarcoma	0.000341	0.00144	CbGpPWpGaD
Rasagiline—Discomfort—Epirubicin—sarcoma	0.00034	0.000557	CcSEcCtD
Rasagiline—Malaise—Doxorubicin—sarcoma	0.000338	0.000553	CcSEcCtD
Rasagiline—Dry mouth—Epirubicin—sarcoma	0.000337	0.000552	CcSEcCtD
Rasagiline—Vertigo—Doxorubicin—sarcoma	0.000336	0.000551	CcSEcCtD
Rasagiline—Syncope—Doxorubicin—sarcoma	0.000336	0.00055	CcSEcCtD
Rasagiline—Leukopenia—Doxorubicin—sarcoma	0.000335	0.000549	CcSEcCtD
Rasagiline—Confusional state—Epirubicin—sarcoma	0.000333	0.000545	CcSEcCtD
Rasagiline—Loss of consciousness—Doxorubicin—sarcoma	0.000329	0.000539	CcSEcCtD
Rasagiline—Infection—Epirubicin—sarcoma	0.000328	0.000537	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000328	0.00139	CbGpPWpGaD
Rasagiline—Cough—Doxorubicin—sarcoma	0.000327	0.000535	CcSEcCtD
Rasagiline—Shock—Epirubicin—sarcoma	0.000325	0.000532	CcSEcCtD
Rasagiline—Convulsion—Doxorubicin—sarcoma	0.000324	0.000531	CcSEcCtD
Rasagiline—Nervous system disorder—Epirubicin—sarcoma	0.000324	0.00053	CcSEcCtD
Rasagiline—Hypertension—Doxorubicin—sarcoma	0.000323	0.000529	CcSEcCtD
Rasagiline—Skin disorder—Epirubicin—sarcoma	0.000321	0.000525	CcSEcCtD
Rasagiline—Hyperhidrosis—Epirubicin—sarcoma	0.000319	0.000523	CcSEcCtD
Rasagiline—Arthralgia—Doxorubicin—sarcoma	0.000319	0.000522	CcSEcCtD
Rasagiline—Chest pain—Doxorubicin—sarcoma	0.000319	0.000522	CcSEcCtD
Rasagiline—Anxiety—Doxorubicin—sarcoma	0.000318	0.00052	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000316	0.000518	CcSEcCtD
Rasagiline—Discomfort—Doxorubicin—sarcoma	0.000315	0.000516	CcSEcCtD
Rasagiline—Anorexia—Epirubicin—sarcoma	0.000315	0.000516	CcSEcCtD
Rasagiline—Dry mouth—Doxorubicin—sarcoma	0.000312	0.000511	CcSEcCtD
Rasagiline—Hypotension—Epirubicin—sarcoma	0.000309	0.000505	CcSEcCtD
Rasagiline—Confusional state—Doxorubicin—sarcoma	0.000308	0.000505	CcSEcCtD
Rasagiline—MAOB—Metabolism—PLCG1—sarcoma	0.000307	0.0013	CbGpPWpGaD
Rasagiline—Infection—Doxorubicin—sarcoma	0.000303	0.000497	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000301	0.000493	CcSEcCtD
Rasagiline—Shock—Doxorubicin—sarcoma	0.000301	0.000492	CcSEcCtD
Rasagiline—Nervous system disorder—Doxorubicin—sarcoma	0.0003	0.000491	CcSEcCtD
Rasagiline—Insomnia—Epirubicin—sarcoma	0.000299	0.000489	CcSEcCtD
Rasagiline—Skin disorder—Doxorubicin—sarcoma	0.000297	0.000486	CcSEcCtD
Rasagiline—Paraesthesia—Epirubicin—sarcoma	0.000296	0.000486	CcSEcCtD
Rasagiline—Hyperhidrosis—Doxorubicin—sarcoma	0.000295	0.000484	CcSEcCtD
Rasagiline—Dyspnoea—Epirubicin—sarcoma	0.000294	0.000482	CcSEcCtD
Rasagiline—Somnolence—Epirubicin—sarcoma	0.000294	0.000481	CcSEcCtD
Rasagiline—Anorexia—Doxorubicin—sarcoma	0.000291	0.000477	CcSEcCtD
Rasagiline—Dyspepsia—Epirubicin—sarcoma	0.000291	0.000476	CcSEcCtD
Rasagiline—Decreased appetite—Epirubicin—sarcoma	0.000287	0.00047	CcSEcCtD
Rasagiline—Hypotension—Doxorubicin—sarcoma	0.000285	0.000468	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Epirubicin—sarcoma	0.000285	0.000467	CcSEcCtD
Rasagiline—Constipation—Epirubicin—sarcoma	0.000282	0.000463	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—MDM2—sarcoma	0.000282	0.00119	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000279	0.00118	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000278	0.000456	CcSEcCtD
Rasagiline—Insomnia—Doxorubicin—sarcoma	0.000276	0.000453	CcSEcCtD
Rasagiline—Paraesthesia—Doxorubicin—sarcoma	0.000274	0.000449	CcSEcCtD
Rasagiline—BCL2—Immune System—FOXO1—sarcoma	0.000274	0.00116	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PDGFRB—sarcoma	0.000273	0.00116	CbGpPWpGaD
Rasagiline—Dyspnoea—Doxorubicin—sarcoma	0.000272	0.000446	CcSEcCtD
Rasagiline—Feeling abnormal—Epirubicin—sarcoma	0.000272	0.000446	CcSEcCtD
Rasagiline—Somnolence—Doxorubicin—sarcoma	0.000272	0.000445	CcSEcCtD
Rasagiline—Gastrointestinal pain—Epirubicin—sarcoma	0.00027	0.000442	CcSEcCtD
Rasagiline—BCL2—Immune System—PDGFRA—sarcoma	0.000269	0.00114	CbGpPWpGaD
Rasagiline—Dyspepsia—Doxorubicin—sarcoma	0.000269	0.000441	CcSEcCtD
Rasagiline—Decreased appetite—Doxorubicin—sarcoma	0.000266	0.000435	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000264	0.000432	CcSEcCtD
Rasagiline—Urticaria—Epirubicin—sarcoma	0.000262	0.00043	CcSEcCtD
Rasagiline—Constipation—Doxorubicin—sarcoma	0.000261	0.000428	CcSEcCtD
Rasagiline—Body temperature increased—Epirubicin—sarcoma	0.000261	0.000428	CcSEcCtD
Rasagiline—Abdominal pain—Epirubicin—sarcoma	0.000261	0.000428	CcSEcCtD
Rasagiline—Feeling abnormal—Doxorubicin—sarcoma	0.000252	0.000412	CcSEcCtD
Rasagiline—Gastrointestinal pain—Doxorubicin—sarcoma	0.00025	0.000409	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—JUN—sarcoma	0.000245	0.00104	CbGpPWpGaD
Rasagiline—Hypersensitivity—Epirubicin—sarcoma	0.000243	0.000398	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CTNNB1—sarcoma	0.000243	0.00103	CbGpPWpGaD
Rasagiline—Urticaria—Doxorubicin—sarcoma	0.000243	0.000398	CcSEcCtD
Rasagiline—Abdominal pain—Doxorubicin—sarcoma	0.000241	0.000396	CcSEcCtD
Rasagiline—Body temperature increased—Doxorubicin—sarcoma	0.000241	0.000396	CcSEcCtD
Rasagiline—Asthenia—Epirubicin—sarcoma	0.000237	0.000388	CcSEcCtD
Rasagiline—Pruritus—Epirubicin—sarcoma	0.000234	0.000383	CcSEcCtD
Rasagiline—Diarrhoea—Epirubicin—sarcoma	0.000226	0.00037	CcSEcCtD
Rasagiline—Hypersensitivity—Doxorubicin—sarcoma	0.000225	0.000369	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—SRC—sarcoma	0.00022	0.000931	CbGpPWpGaD
Rasagiline—Asthenia—Doxorubicin—sarcoma	0.000219	0.000359	CcSEcCtD
Rasagiline—Dizziness—Epirubicin—sarcoma	0.000218	0.000358	CcSEcCtD
Rasagiline—Pruritus—Doxorubicin—sarcoma	0.000216	0.000354	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—NRAS—sarcoma	0.000211	0.000896	CbGpPWpGaD
Rasagiline—Vomiting—Epirubicin—sarcoma	0.00021	0.000344	CcSEcCtD
Rasagiline—Diarrhoea—Doxorubicin—sarcoma	0.000209	0.000342	CcSEcCtD
Rasagiline—BCL2—Immune System—KIT—sarcoma	0.000209	0.000883	CbGpPWpGaD
Rasagiline—Rash—Epirubicin—sarcoma	0.000208	0.000341	CcSEcCtD
Rasagiline—Dermatitis—Epirubicin—sarcoma	0.000208	0.000341	CcSEcCtD
Rasagiline—Headache—Epirubicin—sarcoma	0.000207	0.000339	CcSEcCtD
Rasagiline—Dizziness—Doxorubicin—sarcoma	0.000202	0.000331	CcSEcCtD
Rasagiline—BCL2—Immune System—CREB1—sarcoma	0.000198	0.000841	CbGpPWpGaD
Rasagiline—Nausea—Epirubicin—sarcoma	0.000196	0.000321	CcSEcCtD
Rasagiline—Vomiting—Doxorubicin—sarcoma	0.000194	0.000318	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—EGFR—sarcoma	0.000193	0.000816	CbGpPWpGaD
Rasagiline—Rash—Doxorubicin—sarcoma	0.000193	0.000316	CcSEcCtD
Rasagiline—Dermatitis—Doxorubicin—sarcoma	0.000192	0.000315	CcSEcCtD
Rasagiline—Headache—Doxorubicin—sarcoma	0.000191	0.000314	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—KRAS—sarcoma	0.000182	0.000771	CbGpPWpGaD
Rasagiline—Nausea—Doxorubicin—sarcoma	0.000181	0.000297	CcSEcCtD
Rasagiline—BCL2—Immune System—MDM2—sarcoma	0.000164	0.000696	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HRAS—sarcoma	0.000155	0.000655	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL2—sarcoma	0.000147	0.000622	CbGpPWpGaD
Rasagiline—BCL2—Immune System—JUN—sarcoma	0.000143	0.000605	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTNNB1—sarcoma	0.000142	0.0006	CbGpPWpGaD
Rasagiline—BCL2—Immune System—SRC—sarcoma	0.000128	0.000542	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NRAS—sarcoma	0.000123	0.000522	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGFR—sarcoma	0.000112	0.000475	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—sarcoma	0.000106	0.000449	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HRAS—sarcoma	9.01e-05	0.000382	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ENO2—sarcoma	8.37e-05	0.000355	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HBA1—sarcoma	8.32e-05	0.000352	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PLCG1—sarcoma	7.1e-05	0.000301	CbGpPWpGaD
